Typically vacuous commentary by Zacks: http://finance.yahoo.com/news/Marginal-Beat-for-zacks-1970609535.html?x=0&.v=1 Pfizer will face additional challenges later this year with the loss of US exclusivity on Lipitor in November. LOL—as though investors did not know this already.